Roche struck a licensing and commercialization agreement with Freenome worth potentially more than $200 million — including a $75 million equity stake — to commercialize Freenome’s blood‑based cancer screening tests outside the U.S. Roche will develop kit-based distributed versions while Freenome retains U.S. rights and centralized testing. The deal pairs Freenome’s cfDNA and multiomic assays with Roche’s global diagnostics footprint and upcoming Axelios SBX sequencing platform. The agreement includes milestones and royalties and gives Freenome access to Roche plasma cohorts and technologies to speed product development and regulatory submissions. The partnership highlights diagnostics firms’ strategic drive to combine molecular early‑detection platforms with global commercialization partners, and it positions both firms to capture growing demand for noninvasive cancer screening outside the U.S.